Benzinga | Jan 14, 2021 08:11AM EST

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications; USPTO Withdrew Clarus Application From Issue

SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") declared Interference No. 106,128 between Lipocine, Inc. ("the Senior Party") owned U.S. Patent Application and Clarus Therapeutics, Inc. ("the Junior Party") owned U.S. Patent Application. In preparation for the Interference, the USPTO withdrew the Clarus Application from issue.

This follows the pattern of previous Interferences as shown below:

* Interference No. 106,045 decided in Lipocine's favor and resulted in the cancellation of Clarus patent 8,828,428.

* Interference No. 106,120 decided in Lipocine's favor and resulted in the cancellation of Clarus application 15/723,976.

"We are pleased with the actions and judgements ordered by the PTAB which validates the strength of Lipocine's patent portfolio," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine.